Cooley’s 2022 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 25, 2023
Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. However, given the headwinds facing the acquisition market, smaller life sciences companies were willing to enter into option deals even for Phase 2 assets.
40 
Let's personalize your content